Revolutionary test spares millions of cancer patients from chemotherapy

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleA revolutionary genomic test, Prosigna, could spare millions of breast cancer patients from chemotherapy, a clinical trial has shown. The Optima trial observed over 4,400 women and men aged 40 or older with hormone-sensitive breast cancer, who would typically receive chemotherapy. Participants with a low Prosigna score, indicating low gene activity, were treated with hormone therapy alone. Those with high scores received chemotherapy and hormone therapy. Results showed that five years after treatment, 93.6 per cent of low-scoring patients treated with hormone therapy alone were alive and recurrence-free, comparable to the 94.8 per cent who also received chemotherapy. In fullMillions of breast cancer patients could avoid chemotherapy with new genome testThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in

Raccontata datheguardian.comindependent.co.uk